SRANC

Self Reporting Asymmetric Nucleophilic Catalysis

Coordinatore	THE UNIVERSITY OF BIRMINGHAM    more  Organization address address: Edgbaston city: BIRMINGHAM postcode: B15 2TT contact info Titolo: Ms. Nome: May Cognome: Chung Email: send email Telefono: 441214000000 Fax: 441214000000
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	278˙807 €
EC contributo	278˙807 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-IIF
Funding Scheme	MC-IIF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2015-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF BIRMINGHAM  Organization address address: Edgbaston city: BIRMINGHAM postcode: B15 2TT contact info Titolo: Ms. Nome: May Cognome: Chung Email: send email Telefono: 441214000000 Fax: 441214000000	UK (BIRMINGHAM)	coordinator	278˙807.40

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The energy efficient synthesis of complex molecules from readily accessible starting materials remains a key challenge of the natural sciences, catalysis can address this important challenge. This project draws together the disparate disciplines of catalysis and sensing to deliver new understanding and new functionality towards the synthesis of the next generation of molecules for health. By exploiting the best technology in the sensing arena in combination with synthetic expertise will offer a new paradigm in the approach to tackling synthetic challenges that the team draw together here is ideally equipped to tackle and deliver significant scientific and societal benefits. New catalysts which can sense their own efficacy will be at the heart of the proposed research. Through rapid screening facilitated by the unique sensing regime translated from chemical sensors into catalysis will permit new and exciting synthesis be realised. As such drug molecules that were previously inaccessible for commercial exploitation due to efficiency and selectivity concerns will be realised.'